BCR/ABL-negative clonogenic hematopoietic cells do not accumulate in the plastic-adherent fraction of peripheral blood mononuclear cells from patients with chronic myeloid leukemia in stable chronic phase.
PBMNC from patients with CML and healthy control persons were separated into plastic-adherent and nonadherent cell fractions. A colony assay in semi-solid medium was used to estimate the number and lineage commitment of CFC in each of the fractions. The CML blood-derived colonies were isolated and analyzed by FISH for BCR/ABL sequences. Thus, we were able to test the hypothesis whether a selective enrichment is possible of normal progenitor cells in the blood of CML patients in stable chronic phase after HU and/or IFN. Although the number of leukocytes differed considerably between patients at diagnosis and in stable chronic phase, the proportion of adherent and nonadherent cells was about the same in all preparations tested. There were also only minor differences of adherence between MNC of CML and normal origin. Furthermore, BCR/ABL-positive and negative colonies were equally distributed among unseparated, adherent, and nonadherent PBMNC fractions. In conclusion, an accumulation of BCR/ABL-negative CFC was not found in any of the PBMNC fractions. CFC from PBMNC of the same lineage commitment were simultaneously present in plastic-adherent and nonadherent cell fractions, indicating that their surface charges might be different and, on the other hand, that different lineage commitment precursors can be present in either of the fractions irrespective of CML or blood origin.
Schultheis
B
B
III. Medizinische Klinik, Fakultät für Klinische Medizin der Universität Heidelberg, Germany.
Pasternak
G
G
Hehlmann
R
R
D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D016465:Bone Marrow Purging / Q000379:methods*; D002448:Cell Adhesion; D002469:Cell Separation / Q000379:methods*; D003114:Colony-Forming Units Assay; D016044:Fusion Proteins, bcr-abl / Q000097:blood*; D006412:Hematopoietic Stem Cells / Q000166:cytology*; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D017404:In Situ Hybridization, Fluorescence; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D015466:Leukemia, Myeloid, Chronic-Phase / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D009360:Neoplastic Cells, Circulating; D014411:Neoplastic Stem Cells / Q000473:pathology*; D010969:Plastics; D017211:Treatment Failure; D014410:Tumor Stem Cell Assay
D018906:Antineoplastic Agents, Alkylating; D014408:Biomarkers, Tumor; D007155:Immunologic Factors; D016898:Interferon-alpha; D010969:Plastics; D016044:Fusion Proteins, bcr-abl; D006918:Hydroxyurea